Christopher M Hall

US Patent:

20180334424, Nov 22, 2018

Filed:

May 17, 2018

Appl. No.:

15/982644

Inventors:

- Cleveland OH, US
George William FARR - Rocky River OH, US
Paul Robert MCGUIRK - Spring Hill FL, US
Christopher H. HALL - Shaker Heights OH, US
Walter F. BORON - Shaker Heights OH, US

International Classification:

C07C 235/64
C07F 9/12
C07D 295/185
A61K 31/6615
A61K 31/167
A61K 31/5375
A61K 31/24
A61K 31/661

Abstract:

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

US Patent:

20150342967, Dec 3, 2015

Filed:

Jun 27, 2015

Appl. No.:

14/752839

Inventors:

- Cleveland OH, US
George William FARR - Rocky River OH, US
Paul Robert MCGUIRK - Spring Hill FL, US
Christopher H. HALL - Shaker Heights OH, US
Walter F. BORON - Shaker Heights OH, US

International Classification:

A61K 31/661

Abstract:

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

US Patent:

20150133405, May 14, 2015

Filed:

May 8, 2013

Appl. No.:

14/398947

Inventors:

- Cleveland OH, US
George William Farr - Rocky River OH, US
Paul Robert Mcguirk - Waterford CT, US
Christopher H. Hall - Shaker Heights OH, US
Walter F. Boron - Shaker Heights OH, US

International Classification:

C07C 235/64
C07F 9/12
C07D 295/185

US Classification:

514119, 514622, 5142375, 514546, 564179, 558190, 435375

Abstract:

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

Address:

4701 Pecanwood Way, Knoxville, TN 37921

Phone:

8652124849

VIN:

WAUFFAFL4CN013192

Make:

AUDI

Model:

A4

Year:

2012